Routine exercise ameliorates the metabolic side-effects of treatment with the atypical antipsychotic drug olanzapine in rats. (Q47762878)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23953063%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

title

Routine exercise ameliorates the metabolic side-effects of treatment with the atypical antipsychotic drug olanzapine in rats (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23953063%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23953063%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Ric M Procyshyn

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23953063%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

William G. Honer

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23953063%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Alasdair M Barr

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23953063%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

author name string

H N Boyda

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23953063%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

E Töpfer

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23953063%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

N Lant

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23953063%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

H H T Choy

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23953063%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

R Wong

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23953063%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

L Li

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23953063%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

C C Y Pang

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23953063%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

publication date

19 August 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23953063%20AND%20SRC:MED&resulttype=core&format=json

The International Journal of Neuropsychopharmacology

7 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23953063%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23953063%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23953063%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

page(s)

77-90

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23953063%20AND%20SRC:MED&resulttype=core&format=json

A parametric analysis of olanzapine-induced weight gain in female rats

7 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000795

Potential mechanisms of atypical antipsychotic-induced metabolic derangement: clues for understanding obesity and novel drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000795

Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000795

Insulin resistance and secretion in vivo: effects of different antipsychotics in an animal model

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000795

Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000795

Elevation of systolic blood pressure in an animal model of olanzapine induced weight gain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000795

Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000795

Insulin resistance following continuous, chronic olanzapine treatment: an animal model

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000795

Description of a healthy lifestyle intervention for people with serious mental illness taking second-generation antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000795

Prevalence, correlates, and disease patterns of antipsychotic use in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000795

Chlorpromazine exacerbates hepatic insulin sensitivity via attenuating insulin and leptin signaling pathway, while exercise partially reverses the adverse effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000795

Prediabetes in patients treated with antipsychotic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000795

Preclinical models of antipsychotic drug-induced metabolic side effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000795

Simultaneous determination of five antipsychotic drugs in rat plasma by high performance liquid chromatography with ultraviolet detection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000795

Comparative effects of the antipsychotics sulpiride or risperidone in rats. I: bodyweight, food intake, body composition, hormones and glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000795

Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000795

Olanzapine treatment and metabolic dysfunction: a dose response study in female Sprague Dawley rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000795

Rosiglitazone in the assistance of metabolic control during olanzapine administration in schizophrenia: a pilot double-blind, placebo-controlled, 12-week trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000795

Cardiovascular side-effects of antipsychotic drugs: the role of the autonomic nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000795

Sensitivity of the female rat to olanzapine-induced weight gain--far from the clinic?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000795

Pharmacological management of atypical antipsychotic-induced weight gain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000795

Adaptations to exercise training within skeletal muscle in adults with type 2 diabetes or impaired glucose tolerance: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000795

Effect of exercise on circulating levels of brain-derived neurotrophic factor (BDNF) in overweight and obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000795

Exercise increases skeletal muscle GLUT4 gene expression in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000795

Effects of olanzapine and haloperidol on the metabolic status of healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000795

Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000795

Early perturbation in feeding behaviour and energy homeostasy in olanzapine-treated rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000795

Metabolic obesity: the paradox between visceral and subcutaneous fat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000795

Exercise therapy in type 2 diabetes: is daily exercise required to optimize glycemic control?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000795

Systematic Review and Meta-analysis of Pharmacological Interventions for Weight Gain from Antipsychotics and Mood Stabilizers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000795

Acute clozapine exposure in vivo induces lipid accumulation and marked sequential changes in the expression of SREBP, PPAR, and LXR target genes in rat liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000795

Investigation into the influence of a high fat diet on antipsychotic-induced weight gain in female rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000795

Atypical antipsychotic drugs induce derangements in glucose homeostasis by acutely increasing glucagon secretion and hepatic glucose output in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000795

Olanzapine, but not aripiprazole, weight-independently elevates serum triglycerides and activates lipogenic gene expression in female rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000795

The effect of metformin on anthropometrics and insulin resistance in patients receiving atypical antipsychotic agents: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000795

Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000795

Effects of olanzapine and ziprasidone on glucose tolerance in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000795

Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000795

Exploratory study on association of genetic variation in TBC1D1 with antipsychotic-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000795

Arterial stiffness and stroke in hypertension: therapeutic implications for stroke prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000795

Antipsychotic polypharmacy increases metabolic dysregulation in female rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000795

Evaluation of insulin sensitivity in clinical practice and in research settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000795

Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000795

A double-blind, randomized trial to evaluate the pharmacokinetics and tolerability of 30 or 40 mg/d oral olanzapine relative to 20 mg/d oral olanzapine in stable psychiatric subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000795

Intermittent treatment with olanzapine causes sensitization of the metabolic side-effects in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000795

A parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in an animal model

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000795

Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000795

Exercise training increases insulin-stimulated glucose disposal and GLUT4 (SLC2A4) protein content in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000795

Cytochrome P450 IA2 activity in man measured by caffeine metabolism: effect of smoking, broccoli and exercise

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000795

7 January 2021

Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000795

7 January 2021

Olanzapine effects on body composition, food preference, glucose metabolism and insulin sensitivity in the rat

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000795

7 January 2021

Normal muscle glucose uptake in mice deficient in muscle GLUT4

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000795

7 January 2021

Managing weight gain and metabolic issues in patients treated with atypical antipsychotics.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000795

7 January 2021

Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000795

7 January 2021

Off-label use of atypical antipsychotics: cause for concern?

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000795

7 January 2021

Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000795

7 January 2021

10.1017/S1461145713000795

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23953063%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1 reference